Ocugen (OCGN) Other Non-Current Assets (2014 - 2026)
Ocugen posted quarterly Other Non-Current Assets of $4.2 million for Q1 2026, up 1261.17% year-on-year from $309000.0 in Q1 2025, and up 1231.01% on a QoQ basis from $316000.0 in Q4 2025.
Ocugen (OCGN) has 13 years of Other Non-Current Assets data on file, last reported at $4.2 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 1261.17% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 1261.17% YoY), and the FY2025 full-year result was $316000.0, up 2.93% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $4.2 million, up from $316000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.0 million in Q2 2025 and bottomed at $302000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $1.6 million (2022), against an average of $2.3 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets jumped 2791.39%; it then rose 2.93% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $4.1 million in 2022, then retreated by 3.45% to $3.9 million in 2023, then tumbled by 92.22% to $307000.0 in 2024, then advanced by 2.93% to $316000.0 in 2025, then surged by 1231.01% to $4.2 million in 2026.
- The last three Other Non-Current Assets figures came in at $4.2 million (Q1 2026), $316000.0 (Q4 2025), and $314000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | 4.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.21 Mn |
| Dec 31, 2025 | 316,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | 4.95 Mn |
| Mar 31, 2025 | 309,000.00 |
| Dec 31, 2024 | 307,000.00 |
| Sep 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2023 | 3.95 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 4.23 Mn |
| Jun 30, 2022 | 4.37 Mn |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 151,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Jun 30, 2021 | 151,000.00 |
| Mar 31, 2021 | 151,000.00 |
| Dec 31, 2020 | 714,000.00 |
| Sep 30, 2020 | 151,000.00 |
| Jun 30, 2020 | 151,000.00 |
| Mar 31, 2020 | 151,000.00 |
| Dec 31, 2019 | 151,016.00 |
| Sep 30, 2019 | 150,910.00 |
| Jun 30, 2019 | 150,776.00 |
| Mar 31, 2019 | 150,625.00 |
| Dec 31, 2018 | 116,333.00 |
| Sep 30, 2018 | 150,328.00 |
| Jun 30, 2018 | 137,000.00 |
| Mar 31, 2018 | 137,000.00 |
| Dec 31, 2017 | 137,000.00 |
| Sep 30, 2017 | 137,000.00 |
| Jun 30, 2017 | 137,000.00 |
| Mar 31, 2017 | 137,000.00 |
| Dec 31, 2016 | 10,000.00 |
| Sep 30, 2016 | 137,000.00 |
| Jun 30, 2016 | 137,000.00 |
| Mar 31, 2016 | 137,000.00 |
| Dec 31, 2015 | 137,000.00 |
| Sep 30, 2015 | 137,000.00 |
| Jun 30, 2015 | 137,000.00 |
| Mar 31, 2015 | 604,000.00 |
| Dec 31, 2014 | 505,000.00 |